97 / 144
377
Parkinson’s disease: 5 year follow-up of the CamPaIGN
cohort. Brain. 2009;132(Pt 11):2958-69.
47. Hobson P, Meara J. Mild cognitive impairment in Parkinson’s
disease and its progression onto dementia: a 16-year outcome
evaluation of the Denbighshire cohort. International journal
of geriatric psychiatry. 2015;30(10):1048-55.
48. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen
P. Prevalence and characteristics of dementia in Parkinson
disease: an 8-year prospective study. Archives of neurology.
2003;60(3):387-92.
49. Kempster PA, O’Sullivan SS, Holton JL, Revesz T, Lees
AJ. Relationships between age and late progression of
Parkinson’s disease: a clinico-pathological study. Brain : a
journal of neurology. 2010;133(Pt 6):1755-62.
50. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What
features improve the accuracy of clinical diagnosis in
Parkinson’s disease: a clinicopathologic study. Neurology.
1992;42(6):1142-6.
51. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W,
et al. MDS clinical diagnostic criteria for Parkinson’s disease.
Movement disorders : official journal of the Movement
Disorder Society. 2015;30(12):1591-601.
52. Djaldetti R, Ziv I, Melamed E. The mystery of motor
asymmetry in Parkinson’s disease. The Lancet Neurology.
2006;5(9):796-802.
53. Group TPS. Low-dose clozapine for the treatment of drug-
induced psychosis in Parkinson’s disease. . The New England
journal of medicine. 1999;340(10):757-63.
54. Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol
O, Montastruc JL. Drug-induced parkinsonism: a review of
17 years’ experience in a regional pharmacovigilance center
in France. Movement disorders : official journal of the
Movement Disorder Society. 2011;26(12):2226-31.
55. Williams DR, Litvan I. Parkinsonian syndromes. Continuum.
2013;19(5 Movement Disorders):1189-212.
56. Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M,
Djaldetti R. [123I]-FP/CIT SPECT imaging for distinguishing
drug-induced parkinsonism from Parkinson’s disease. Mov
Disord. 2006;21(4):510-4.
57. Plotkin M, Amthauer H, Klaffke S, Kuhn A, Ludemann L, Arnold
G, et al. Combined 123I-FP-CIT and 123I-IBZM SPECT
for the diagnosis of parkinsonian syndromes: study on 72
patients. Journal of neural transmission. 2005;112(5):677-
92.
58. Sakakibara R, Uchiyama T, Yamanishi T, Kishi M.
Genitourinary dysfunction in Parkinson’s disease. Movement
disorders : official journal of the Movement Disorder Society.
2010;25(1):2-12.
59. Freeman R. Clinical practice. Neurogenic orthostatic
hypotension. The New England journal of medicine.
2008;358(6):615-24.
60. Rajabally YA, Martey J. Neuropathy in Parkinson
disease:
prevalence
and
determinants.
Neurology.
2011;77(22):1947-50.
61. Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn
D, Deuschl G, et al. Summary of the recommendations of
the EFNS/MDS-ES review on therapeutic management
of Parkinson’s disease. European journal of neurology.
2013;20(1):5-15.
62. Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini
P, et al. Priorities in Parkinson’s disease research. Nature
reviews Drug discovery. 2011;10(5):377-93.
63. Hornykiewicz O. 50 years of levodopa. Movement disorders:
official journal of the Movement Disorder Society.
2015;30(7):1008.
64. Tran T, Brophy JM, Suissa S, Renoux C. Risks of Cardiac Valve
Regurgitation and Heart Failure Associated with Ergot- and
Non-Ergot-Derived Dopamine Agonist Use in Patients with
Parkinson’s Disease: A Systematic Review of Observational
Studies. CNS drugs. 2015;29(12):985-98.
65. Nutt JG, Wooten GF. Clinical practice. Diagnosis and initial
management of Parkinson’s disease. The New England
journal of medicine. 2005;353(10):1021-7.
66. Cilia R, Akpalu A, Sarfo FS, Cham M, Amboni M, Cereda E,
et al. The modern pre-levodopa era of Parkinson’s disease:
insights into motor complications from sub-Saharan Africa.
Brain. 2014;137(Pt 10):2731-42.
67. Fox SH, Lang AE. ‘Don’t delay, start today’: delaying levodopa
does not delay motor complications. Brain. 2014;137(Pt
10):2628-30.
68. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE.
Systematic review of levodopa dose equivalency reporting in
Parkinson’s disease. Movement disorders : official journal of
the Movement Disorder Society. 2010;25(15):2649-53.
69. Muller T, Erdmann C, Bremen D, Schmidt WE, Muhlack S,
Woitalla D, et al. Impact of gastric emptying on levodopa
pharmacokinetics in Parkinson disease patients. Clinical
neuropharmacology. 2006;29(2):61-7.
70. Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet.
2009;373(9680):2055-66.
71. Quinn N, Illas A, Lhermitte F, Agid Y. Bromocriptine and
domperidone in the treatment of Parkinson disease.
Neurology. 1981;31(6):662-7.
72. Doggrell SA, Hancox JC. Cardiac safety concerns for
domperidone, an antiemetic and prokinetic, and
galactogogue medicine. Expert opinion on drug safety.
2014;13(1):131-8.
73. Thobois S, Lhommee E, Klinger H, Ardouin C, Schmitt
E, Bichon A, et al. Parkinsonian apathy responds to
dopaminergic stimulation of D2/D3 receptors with piribedil.
Brain. 2013;136(Pt 5):1568-77.
74. Brefel-Courbon C, Payoux P, Thalamas C, Ory F, Quelven
I, Chollet F, et al. Effect of levodopa on pain threshold
in Parkinson’s disease: a clinical and positron emission
tomography study. Mov Disord. 2005;20(12):1557-63.
75. Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M,
Olanow CW. The evolution and origin of motor complications
in Parkinson’s disease. Neurology. 2000;55(11 Suppl
[ACTUALIZACIÓN EN LA ENFERMEDAD DE PARKINSON - Dr. Raúl Martínez-Fernández y cols.]